The U.S. Food and Drug Administration (FDA) has confirmed that it is aware Intuitive Surgical, a medical device manufacturer, has notified affected customers and recommended the removal of certain models of curved staplers from use and sales locations.

**Initiation of Voluntary Product Replacement** Intuitive Surgical stated in a letter to customers that some Curved-Tip Stapler devices may have potential performance deviations. The company recommends that medical institutions immediately inspect their inventory and discontinue use of devices from the affected batches. This action is a company-initiated market corrective measure and has not yet been classified as a mandatory recall. **Stapler Widely Used in Clinical Practice** The Curved-Tip Stapler is a key instrument in laparoscopic surgery, widely used in gastrointestinal resection, organ anastomosis, and other minimally invasive surgical procedures. Intuitive Surgical's da Vinci surgical system is the world's largest installed surgical robot platform, and the safety and reliability of its supporting instruments directly impact surgical outcomes. The products involved in this incident are consumable instruments frequently used with the system. **Regulatory Follow-Up and Market Attention** The FDA stated it is following up on the incident but has not disclosed specific models, batches, or potential risk details of the affected devices. According to regulatory procedures, if subsequent assessments confirm safety hazards, the action may be upgraded to a Class II or Class III recall. Following this news, Intuitive Surgical's stock price showed limited fluctuation in after-hours trading on Wednesday, with the market generally believing that the voluntary replacement measure reflects the company's quality management awareness. **Ongoing Industry Compliance Developments** Over the past year, the FDA has strengthened post-market supervision of surgical robots and high-value consumables, with several medical device companies facing product recalls or safety warnings. Industry analysts point out that as the penetration rate of minimally invasive surgery increases, product traceability and risk management of surgical instruments will become key areas of regulatory focus.